Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has
added a novel new system to its CELLestial™ line of live cell analysis
products, providing expanded capability to simultaneously image both the
nucleus and the nucleolus in living cells, the Company announced today.
Called the Total Nuclear-ID™ Green/Red Nucleolar/Nuclear
Detection Kit, the new addition has been specifically optimized for
demanding live cell microscopy applications.
The new system was featured in a recent issue of the publication "Microscopy
Today,” in an article entitled "Red/Green Dual Fluorescence
Detection of Both the Nucleus and Nucleolus in Living Cells.” In
addition, Wayne Patton, Ph.D., Chief Scientific Officer for Enzo Life
Sciences, presented a poster at the prestigious Microscopy and
Microanalysis 2009 conference, held recently in Richmond, VA, on the
utility of the kit for various drug discovery and basic cell biology
applications.
"This complete system adds significant capabilities to our growing
portfolio of live cell fluorescent probes to address unmet investigator
needs,” said Dr. Patton. "The CELLestial™ product line encompasses a
range of products optimized for various instrument platforms, including
microscopes, microplate readers, flow cytometers and laser-scanning
cytometers. Its introduction underscores our continuing commitment to
introducing novel assay technologies that address rapidly expanding
research fields and core applications in the Life Sciences."
The system contains proprietary dyes that are highly resistant to
photobleaching and concentration quenching, ensuring strong, consistent
fluorescence signal, even after extended viewing periods. It has been
validated for use in live cell imaging applications, demonstrating
appropriate response to treatment with well-characterized
nucleolus-perturbing drugs. Potential applications for this kit include
monitoring impaired ribosome biogenesis, inhibition of transcription,
cell cycle dynamics and cellular stress, as well as the distribution,
trafficking and dynamics of nucleolar proteins, the distribution of
viral proteins, and potentially as an aid in identifying neoplastic
cells.
As a world leader in non-radioactive probe technology, Enzo has now
developed a wide range of products for the study of nucleic acids, as
well as cellular components.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its catalog of over 30,000 products
serves the molecular biology, drug discovery and pathology research
markets. The Company's therapeutic division is in various stages of
clinical evaluation of its proprietary immune regulation medicines for
uveitis and Crohn's disease and conducts pre-clinical research on
several candidate compounds aimed at producing new mineral and organic
bone, including technology that could provide therapy for osteoporosis
and fractures, among other applications. Enzo’s Clinical Labs division
provides routine and esoteric reference laboratory services for
physicians in the New York Metropolitan and New Jersey areas.
Underpinning the Company’s technology and operations is an extensive
intellectual property estate in which Enzo owns or licenses over 240
patents worldwide, and has pending applications for over 200 more. For
more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
